

Furosemide Solid Formulation

Commission Regulation (EU) 2020/878

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	658059-00018	Date of first issue: 03.05.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier		
Trade name	:	Furosemide Solid Formulation
1.2 Relevant identified uses o	of the s	ubstance or mixture and uses advised against
Use of the Sub- stance/Mixture	:	Veterinary product
Recommended restrictions on use	6 :	Not applicable
1.3 Details of the supplier of t	he safe	ety data sheet
Company	:	MSD Kilak as lan
		Kilsheelan Clonmel Tipperary, IE
Telephone	:	353-51-601000
E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION	N (EC) No	1272/2008)
Constitution to reach a reach to visit	ropotod	11070.0

Specific target organ toxicity - repeated exposure, Category 1

H372: Causes damage to organs through prolonged or repeated exposure.

2.2 Label elements

Signal word

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

-	
:	Danger

۸

Hazard statements : H372

Causes damage to organs through prolonged or repeated exposure.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Furosemide Solid Formulation

Version 4.3	Revision Date: 28.09.2024	SDS Number: 658059-00018	Date of last issue: 06.04.2024 Date of first issue: 03.05.2016
Preca	nutionary statements	: Prevention P260 P264 P270	: Do not breathe dust. Wash skin thoroughly after handling. Do not eat, drink or smoke when using this prod-
		Response:	uct.
		P314	Get medical advice/ attention if you feel unwell.

Hazardous components which must be listed on the label:

Furosemide

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Furosemide	54-31-9 200-203-6	STOT RE 1; H372 (Kidney, Liver)	>= 10 - < 20

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice

: In the case of accident or if you feel unwell, seek medical advice immediately.

When symptoms persist or in all cases of doubt seek medical advice.



Furosemide Solid Formulation

Version 4.3	Revision Date: 28.09.2024		9S Number: 8059-00018	Date of last issue: 06.04.2024 Date of first issue: 03.05.2016			
Prote	ction of first-aiders	:	and use the recor	ers should pay attention to self-protection, nmended personal protective equipment I for exposure exists (see section 8).			
lf inha	aled	:	If inhaled, remove Get medical atten	e to fresh air. tion if symptoms occur.			
In cas	e of skin contact	:	of water.	, immediately flush skin with soap and plenty tion if symptoms occur.			
In cas	se of eye contact	:	If in eyes, rinse w Get medical atten	ell with water. tion if irritation develops and persists.			
lf swa	llowed	:		NOT induce vomiting. tion if symptoms occur. oughly with water.			
4.2 Most important symptoms and effects, both acute and delayed							
Risks		:	Causes damage t exposure.	o organs through prolonged or repeated			
			the skin.	can cause mechanical irritation or drying of the eyes can lead to mechanical irritation.			
4 3 Indica	tion of any immediate	mor	lical attention and	special treatment needed			
Treat	-	:		cally and supportively.			
SECTION	I 5: Firefighting mea	sur	es				
5.1 Exting	uishing media						
Suital	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical				
Unsui media	table extinguishing	:	None known.				
	al hazarde arising from	the	substance or mi	xture			
D.Z ODECIA	a nazalus ansing nom	-					
-	fic hazards during fire-	:	concentrations, and potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. Dustion products may be a hazard to health.			



Furosemide Solid Formulation

Vers 4.3	sion	Revision Date: 28.09.2024		DS Number: 8059-00018	Date of last issue: 06.04.2024 Date of first issue: 03.05.2016		
				Sulphur oxides Chlorine compour	nds		
5.3 Advice for firefighters							
Special protective equipment for firefighters		:		e, wear self-contained breathing apparatus. tective equipment.			
Specific extinguishing meth- ods		:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to d so. Evacuate area.				

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.
		Local authorities should be advised if significant s cannot be contained.

6.3 Methods and material for containment and cleaning up

posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable.	Methods for cleaning up	employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding
--	-------------------------	--

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Furosemide Solid Formulation

Vers 4.3	sion	Revision Date: 28.09.2024		DS Number: 8059-00018	Date of last issue: 06.04.2024 Date of first issue: 03.05.2016
	Techni	cal measures	:	causing an explore Provide adequate	nay accumulate and ignite suspended dust sion. e precautions, such as electrical grounding nert atmospheres.
	Advice	Fotal ventilation on safe handling		Use only with ade Do not breathe de Do not swallow. Avoid contact with Avoid prolonged Wash skin thorou Handle in accord practice, based o sessment Minimize dust get Keep container co Keep away from Take precautiona Do not eat, drink Take care to prevent.	equate ventilation. ust. h eyes. or repeated contact with skin. ughly after handling. ance with good industrial hygiene and safety in the results of the workplace exposure as- neration and accumulation. losed when not in use. heat and sources of ignition. ary measures against static discharges. or smoke when using this product. vent spills, waste and minimize release to the
	Hygien	e measures	:	flushing systems place. When usin nated clothing be The effective ope engineering contr appropriate dego	eration of a facility should include review of rols, proper personal protective equipment, wning and decontamination procedures, e monitoring, medical surveillance and the
7.2 (Conditi	ons for safe storage,	inc	luding any incom	patibilities
		ements for storage and containers	:	Keep in properly the particular nat	labelled containers. Store in accordance with ional regulations.
	Advice	on common storage	:	Strong oxidizing	stances and mixtures
7.3 \$	Specifi	c end use(s)			
	-	c use(s)	:	No data available	

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dusts non-specific

4 mg/m3 Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Furosemide Solid Formulation

/ersion .3	Revision Dat 28.09.2024			Date of last issue: 06.04.2024 Date of first issue: 03.05.2016	
		Ba 10 Va du	ust) asis: IE OEL) mg/m3 alue type (Form of ust) asis: IE OEL	exposure): OELV - 8 hrs (TV	/A) (inhalable
Comp	onents	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Starch	٦	9005-25-8	OELV - 8 hrs (TWA) (Respira- ble dust)	4 mg/m3	IE OEL
			OELV - 8 hrs (TWA) (inhalable dust)	10 mg/m3	IE OEL
Furos	emide	54-31-9	TWÁ	200 µg/m3	Internal
			TWA	OEB 2 (>=100 - 1000 ug/m3)	Internal
Cellul	ose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipm	nent	
Eye/face protection :		Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Skin and body protection Respiratory protection	:	Work uniform or laboratory coat. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143
Filter type	:	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

	-	-		
Physical state			:	powder

Colour

: yellow

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Furosemide Solid Formulation

Vers 4.3	sion	Revision Date: 28.09.2024		S Number: 059-00018	Date of last issue: 06.04.2024 Date of first issue: 03.05.2016
	Odour		:	No data available	
	Odour ⁻	Threshold	:	No data available	
	Melting	point/freezing point	:	No data available	
	Initial be range	oiling point and boiling	:	No data available	
	Flamma	ability (solid, gas)	:	May form explosi dling or other me	ve dust-air mixture during processing, han- ans.
	Flamma	ability (liquids)	:	No data available	
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available	
	Flash p	oint	:	Not applicable	
	Auto-ig	nition temperature	:	No data available	
	Decom	position temperature	:	No data available	
	рН		:	No data available	
	Viscosi Visc	ty osity, kinematic	:	No data available	
	Solubili Wat	ty(ies) er solubility	:	No data available	
	Partition octanol	n coefficient: n- /water	:	No data available	
	Vapour	pressure	:	No data available	
	Relative	e density	:	No data available	
	Density	,	:	No data available	
	Relative	e vapour density	:	No data available	
		characteristics icle size	:	No data available	

9.2 Other information

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Furosemide Solid Formulation

Version 4.3	Revision Date: 28.09.2024		9S Number: 8059-00018	Date of last issue: 06.04.2024 Date of first issue: 03.05.2016
Explo	osives	:	Not explosive	
Oxidi	zing properties	:	The substance of	or mixture is not classified as oxidizing.
Evap	oration rate	:	No data availabl	e
Mole	cular weight	:	Not applicable	

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions :	May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.		
10.4 Conditions to avoid			
Conditions to avoid :	Heat, flames and sparks. Avoid dust formation.		
10.5 Incompatible materials			
Materials to avoid	Oxidizing agents		
10.6 Hazardous decomposition products			

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation exposure Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Furosemide:

Acute oral toxicity	:	LD50 (Rat): 2,600 mg/kg
		LD50 (Dog): 2,000 mg/kg
		LD50 (Rabbit): 800 mg/kg



Furosemide Solid Formulation

Version 4.3	Revision Date: 28.09.2024	-	0S Number: 8059-00018	Date of last issue: 06.04.2024 Date of first issue: 03.05.2016
	e toxicity (other routes of nistration)	:	LD0 (Humans): 6 Application Route	
			LD50 (Rat): 800 r Application Route	
	corrosion/irritation	able	information.	
	ous eye damage/eye irr lassified based on availa			
Resp	iratory or skin sensitis	atio	on	
-	sensitisation lassified based on availa	able	information.	
-	iratory sensitisation lassified based on availa	able	information.	
	n cell mutagenicity lassified based on availa	able	information.	
<u>Com</u>	ponents:			
	semide: otoxicity in vitro	:	Test Type: Bacter Result: negative	rial reverse mutation assay (AMES)
				o mammalian cell gene mutation test use lymphoma cells
			thesis in mammal	damage and repair, unscheduled DNA syn- lian cells (in vitro) nmalian liver cells
				nosome aberration test in vitro nese hamster ovary cells
			malian cells	o sister chromatid exchange assay in mam- nese hamster cells
Genc	otoxicity in vivo	:	Test Type: Mamn cytogenetic assay Species: Mouse Application Route Result: negative	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Furosemide Solid Formulation

Version 4.3	Revision Date: 28.09.2024		9S Number: 8059-00018	Date of last issue: 06.04.2024 Date of first issue: 03.05.2016
	nogenicity assified based on avail	able	information.	
<u>Comp</u>	oonents:			
Furos	semide:			
	cation Route sure time L	:	Rat Ingestion 104 weeks 16 mg/kg body we equivocal	eight
	cation Route sure time L	:	Mouse Ingestion 2 Years 91 mg/kg body we positive	eight
Not cl	oductive toxicity assified based on avail	able	information.	
Comp	oonents:			
	semide:			
Effect	s on fertility	:	Species: Rat Application Route General Toxicity - Result: No effects Test Type: One-g Species: Mouse Application Route General Toxicity -	Parent: NOAEL: 90 mg/kg body weight s on reproduction parameters eneration reproduction toxicity study
Effect ment	s on foetal develop-	:	Species: Rat Application Route General Toxicity I Developmental To Result: No embry	Maternal: LOAEL: 50 mg/kg body weight oxicity: NOAEL: 300 mg/kg body weight otoxic effects, No teratogenic effects y/early embryonic development

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Furosemide Solid Formulation

Version 4.3	Revision Date: 28.09.2024	SDS Number: 658059-00018	Date of last issue: 06.04.2024 Date of first issue: 03.05.2016
		Result: Maternal Test Type: Fertil Species: Rabbit Application Rout General Toxicity	Maternal: LOAEL: 25 mg/kg body weight toxicity observed., Fetal effects ity/early embryonic development e: Ingestion Maternal: LOAEL: <= 12 mg/kg body weight Foxicity: LOAEL: 12.5 mg/kg body weight
		•	toxicity observed., Reduced number of viable
		Species: Rabbit Application Rout General Toxicity	ity/early embryonic development e: Ingestion Maternal: LOAEL: 15 mg/kg body weight toxicity observed., No effects on foetal de-

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Furosemide:

Exposure routes Target Organs Assessment	:	Ingestion Kidney Shown to produce significant health effects in animals at con-
		centrations of 10 mg/kg bw or less.

Repeated dose toxicity

Components:

Furosemide:

Species :	Dog
NOAEL :	4 mg/kg
LOAEL :	8 mg/kg
Application Route :	Ingestion
Exposure time :	12 Months
Target Organs :	Kidney
Symptoms :	Blood disorders
Remarks :	Significant toxicity observed in testing

Aspiration toxicity

Not classified based on available information.



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	658059-00018	Date of first issue: 03.05.2016

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Furosemide:

Inhalation Skin contact		Remarks: May be harmful if inhaled. Remarks: May irritate skin.
Eye contact		Remarks: May cause eye irritation.
Ingestion	:	Symptoms: Kidney disorders, Headache, electrolyte imbal- ance, dry mouth, hearing loss, Irregular cardiac activity, Gas- trointestinal disturbance, hypotension

SECTION 12: Ecological information

12.1 Toxicity

Components:

Furosemide:

Toxicity to fish

: LC50 : 500 mg/l Exposure time: 96 h

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

Components:

Furosemide:

Partition coefficient: n- : log Pow: 2.03 octanol/water

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment

: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of



Furosemide Solid Formulation

Version 4.3	Revision Date: 28.09.2024	SDS Number: 658059-00018	Date of last issue: 06.04.2024 Date of first issue: 03.05.2016		
		0.1% or higher			
12.6 Endocrine disrupting properties					
Prod	uct:				
Asse	ssment	ered to have en REACH Article (EU) 2017/210	: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.		

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods	
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.3 Transport hazard class(es)		
ADN	:	Not regulated as a dangerous good



Furosemide Solid Formulation

Version 4.3	Revision Date: 28.09.2024	SDS Number: 658059-00018	Date of last issue: 06.04.2024 Date of first issue: 03.05.2016
ADR		: Not regulate	ed as a dangerous good
RID		: Not regulate	ed as a dangerous good
IMDO	3	: Not regulate	ed as a dangerous good
ΙΑΤΑ	۱.	: Not regulate	ed as a dangerous good
14.4 Pack	king group		
ADN		: Not regulate	ed as a dangerous good
ADR		: Not regulate	ed as a dangerous good
RID		: Not regulate	ed as a dangerous good
IMDO	3	: Not regulate	ed as a dangerous good
ΙΑΤΑ	(Cargo)	: Not regulate	ed as a dangerous good
ΙΑΤΑ	(Passenger)	: Not regulate	ed as a dangerous good
14.5 Envi	ronmental hazards		
Not r	egulated as a dangero	ous good	
-	cial precautions for un applicable	ser	
14.7 Mari	time transport in bul	k according to IMC) instruments
Rema	arks	: Not applicat	ble for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Seveso III: Directive 2012/18/EU of the European Parliar major-accident hazards involving dangerous substances		t and of the Council on the control of

Not applicable

Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national



Furosemide Solid Formulation

Vers 4.3	ion	Revision Date: 28.09.2024		0S Number: 8059-00018	Date of last issue: 06.04.2024 Date of first issue: 03.05.2016		
	regulat	ions, where applicable.					
		mponents of this pro	duc	•	he following inventories:		
	AICS		:	not determined			
	DSL		:	not determined			
	IECSC		:	not determined			
	15.2 Chemical safety assessment A Chemical Safety Assessment has not been carried out.						
SEC	SECTION 16: Other information						
	Other i	nformation	:		ges have been made to the previous version the body of this document by two vertical		
	Full tex	kt of H-Statements					
	H372		:	Causes damage t exposure.	o organs through prolonged or repeated		
Full text of other abbreviations							
	STOT I IE OEL		:	Ireland. List of Ch	an toxicity - repeated exposure emical Agents and Carcinogens with Occu- e Limit Values - Code of Practice, Schedule 1		
	IE OEL	. / OELV - 8 hrs (TWA)	:	Occupational exp	osure limit value (8-hour reference period)		

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory: LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	658059-00018	Date of first issue: 03.05.2016

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Classification of the mixture		Classification procedure:	
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/	

Classification of the mixture	Classification procedure:	
STOT RE 1	H372	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN